Market Overview:
The global neutropenia drugs market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of cancer, rising awareness about neutropenia and its treatment, and the launch of novel drugs. Based on type, the global neutropenia drugs market is segmented into capsules and injections. The capsules segment is expected to account for a larger share of the market than the injections segment during the forecast period. This can be attributed to factors such as ease-of-use and lower cost compared with injections. Based on application, the global neutropenia drugs market is divided into hospital and clinic settings.
Product Definition:
A decrease in the number of neutrophils in the blood, resulting in a weakened immune system. Neutropenia Drugs are used to treat this condition.
Capsule:
Capsule is a small package of drugs or pharmaceutical products containing drug ingredients. It protects the active ingredient from harsh environments such as stomach acids and digestive enzymes. The size and shape of capsule are designed to deliver optimal dosage to the patient with minimum side effects while ensuring drug stability for a sufficient time period. Capsules can be oral, topical, transdermal or nasal in formulation depending upon the type of administration required by patients.
Injection:
Injection is a medical procedure used to introduce the drug into the patient's body. The drug can be an injectable or oral medication, which is then transported by blood vessels to different parts of the body. Injection allows precise dosing and offers benefits such as ease of administration and improved efficacy compared to other dosage forms like tablets or capsules.
Application Insights:
The hospital application segment led the global neutropenia drugs market in 2017. The segment is projected to expand at a CAGR of XX% over the forecast period owing to an increase in patient admissions for various diseases, such as cancer and infections, which results in low white blood cell count. In addition, a rise in healthcare spending due to increasing prevalence of chronic diseases is expected to drive growth during the forecast period.
Neutropenia occurs when there are too few neutrophils (a type of white blood cells) present in the body; this leads to several complications including infection and reduced ability of body tissues To resist bacterial/fungal infections resulting from low immunity against these microorganisms.
Regional Analysis:
North America dominated the global market in 2017 owing to the presence of a large number of key players. The region is expected to maintain its dominance over the forecast period, with growth primarily driven by U.S.
Asia Pacific is expected witness lucrative growth over the forecast period owing high demand for Neutropenia drugs from emerging countries such as China and India along with other developing nations such as South Korea and Singapore.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is one of the key growth drivers for the neutropenia drugs market. According to a study by the American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in the U.S. in 2017 and around 600,920 people will die from this disease. This growing prevalence of cancer is expected to drive demand for neutropenia drugs in order to manage its associated side effects such as neutropenia.
- Rising geriatric population: The global geriatric population is aging at an alarming rate and this is expected to drive demand for neutropenia drugs over the forecast period. According to a study by United Nations Department of Economic and Social Affairs (UNDESA), it was found that 8% of world’s population was aged 60 or above in 1950 which increased to 11% in 2010 and is projected to reach 22% by 2050. This rising geriatric population is more susceptible to developing diseases such as cancer, which leads to development of neutropenia and hence drives demand for related drugs therapies..
Scope Of The Report
Report Attributes
Report Details
Report Title
Neutropenia Drugs Market Research Report
By Type
Capsule, Injection
By Application
Hospital, Clinic
By Companies
Apotex Inc., Biogenomics Limited, Cellerant Therapeutics, Inc., Coherus BioSciences, Inc., Dr. Reddy’s Laboratories Limited, Ligand Pharmaceuticals, Inc., NAL Pharmaceuticals Ltd., Prolong Pharmaceuticals, LLC, Richter Gedeon Nyrt., Sandoz International GmbH
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
225
Number of Tables & Figures
158
Customization Available
Yes, the report can be customized as per your need.
Global Neutropenia Drugs Market Report Segments:
The global Neutropenia Drugs market is segmented on the basis of:
Types
Capsule, Injection
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Apotex Inc.
- Biogenomics Limited
- Cellerant Therapeutics, Inc.
- Coherus BioSciences, Inc.
- Dr. Reddy’s Laboratories Limited
- Ligand Pharmaceuticals, Inc.
- NAL Pharmaceuticals Ltd.
- Prolong Pharmaceuticals, LLC
- Richter Gedeon Nyrt.
- Sandoz International GmbH
Highlights of The Neutropenia Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Capsule
- Injection
- By Application:
- Hospital
- Clinic
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Neutropenia Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Neutropenia drugs are medications used to treat a decrease in the number of neutrophils (a type of white blood cell) in the blood. Neutropenia can be caused by a variety of factors, including infection, cancer, and chemotherapy.
Some of the major companies in the neutropenia drugs market are Apotex Inc., Biogenomics Limited, Cellerant Therapeutics, Inc., Coherus BioSciences, Inc., Dr. Reddy’s Laboratories Limited, Ligand Pharmaceuticals, Inc., NAL Pharmaceuticals Ltd., Prolong Pharmaceuticals, LLC, Richter Gedeon Nyrt., Sandoz International GmbH.
The neutropenia drugs market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Neutropenia Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Neutropenia Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Neutropenia Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Neutropenia Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Neutropenia Drugs Market Size & Forecast, 2020-2028
4.5.1 Neutropenia Drugs Market Size and Y-o-Y Growth
4.5.2 Neutropenia Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Capsule
5.2.2 Injection
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Neutropenia Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Neutropenia Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Capsule
9.6.2 Injection
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Capsule
10.6.2 Injection
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Capsule
11.6.2 Injection
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Capsule
12.6.2 Injection
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Capsule
13.6.2 Injection
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Neutropenia Drugs Market: Competitive Dashboard
14.2 Global Neutropenia Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Apotex Inc.
14.3.2 Biogenomics Limited
14.3.3 Cellerant Therapeutics, Inc.
14.3.4 Coherus BioSciences, Inc.
14.3.5 Dr. Reddy’s Laboratories Limited
14.3.6 Ligand Pharmaceuticals, Inc.
14.3.7 NAL Pharmaceuticals Ltd.
14.3.8 Prolong Pharmaceuticals, LLC
14.3.9 Richter Gedeon Nyrt.
14.3.10 Sandoz International GmbH
